Provectus Biopharmaceuticals Inc (PVCT) financial statements (2021 and earlier)

Company profile

Business Address 10025 INVESTMENT DRIVE
KNOXVILLE, TN 37932
State of Incorp. DE
Fiscal Year End December 31
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments010011417
Cash and cash equivalents010011417
Receivables 0     
Prepaid expense0000   
Other current assets    001
Other undisclosed current assets0 10011
Total current assets:011121519
Noncurrent Assets
Operating lease, right-of-use asset00
Property, plant and equipment0000000
Intangible assets, net (including goodwill)(12)012234
Intangible assets, net (excluding goodwill)(12)012234
Other noncurrent assets     00
Other undisclosed noncurrent assets12  1133
Total noncurrent assets:0012467
TOTAL ASSETS:112362026
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities5244241
Accounts payable1133220
Accrued liabilities2111000
Interest and dividends payable30     
Settlement liabilities     2 
Debt171     
Due to related parties7      
Other undisclosed current liabilities2      
Total current liabilities:31344241
Noncurrent Liabilities
Long-term debt and lease obligation01314    
Long-term debt, excluding current maturities 1314    
Operating lease, liability00
Liabilities, other than long-term debt 11    
Due to related parties 11    
Other undisclosed noncurrent liabilities(0)819  0
Total noncurrent liabilities:023159  0
Total liabilities:31261913241
Stockholders' equity
Stockholders' equity attributable to parent(30)(24)(17)(10)31625
Preferred stock    0  
Common stock0000000
Additional paid in capital210209209208208197181
Accumulated other comprehensive loss(0)(0)     
Accumulated deficit(240)(234)(227)(219)(205)(181)(156)
Total stockholders' equity:(30)(24)(17)(10)31625
TOTAL LIABILITIES AND EQUITY:112362026

Income statement (P&L) ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Operating expenses(5)(6)(8)(14)(25)(25)(13)
Operating loss:(5)(6)(8)(14)(25)(25)(13)
Nonoperating income (expense)(2)000000
Investment income, nonoperating0000000
Interest and debt expense(2)(1)(1)    
Loss from continuing operations before equity method investments, income taxes:(8)(8)(9)(14)(25)(25)(13)
Other undisclosed income from continuing operations before income taxes811    
Loss from continuing operations before income taxes:(1)(7)(8)(14)(25)(25)(13)
Income tax expense (benefit)(0)22    
Net loss:(1)(5)(6)(14)(25)(25)(13)
Other undisclosed net income (loss) attributable to parent(6)(2)(2)0002
Net loss attributable to parent:(7)(7)(8)(14)(24)(25)(10)
Other undisclosed net loss available to common stockholders, basic   (0)(4)  
Net loss available to common stockholders, diluted:(7)(7)(8)(14)(29)(25)(10)

Comprehensive Income ($ in millions)

12/31/2020
12/31/2019
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net loss:(1)(5)(6)(14)(25)(25)(13)
Other comprehensive loss(0)(0)     
Comprehensive loss:(1)(5)(6)(14)(25)(25)(13)
Other undisclosed comprehensive loss, net of tax, attributable to parent(6)(2)     
Comprehensive loss, net of tax, attributable to parent:(7)(7)(6)(14)(25)(25)(13)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: